PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood (PROMOTE)
Investigating the Effect of 5-HT4 Receptor Agonism on Cognition and Sleep in People With Low Mood
Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells. These receptors act like "locks", with serotonin acting like a "key". Different types of serotonin receptors have different effects in the brain.
Prucalopride is a licensed medication used to treat constipation. It acts on a particular serotonin receptor, called the serotonin 4 receptor. Researchers are interested in this receptor because understanding how it works in the brain may help us learn more about depression and could contribute to the development of new treatments in the future.
The purpose of this study is to investigate the effects of prucalopride in people experiencing low mood. We will compare prucalopride with a placebo (a treatment with no active medication) to find out whether activating the serotonin 4 receptor affects sleep and aspects of thinking, including memory, attention and decision making.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Cognitive symptoms are common in depression and can persist even when other symptoms of depression have improved. These difficulties can include impairments in memory, attention and executive function, and there remains a need for treatments that specifically target cognitive dysfunction associated with depression.
Evidence from preclinical and human experimental studies suggests that activation of the serotonin 4 receptor (5-HT4R) may represent a potential therapeutic approach for targeting cognitive symptoms in depression. The 5-HT4R is expressed in brain regions involved in learning and memory, and experimental studies have investigated whether selective activation of this receptor can influence cognitive processes relevant to depression.
Prucalopride is a selective 5-HT4R agonist. In previous human experimental studies, we have found evidence that prucalopride can influence cognitive processes, including learning and memory, in healthy volunteers and people who have recovered from depression. The present study extends this work by investigating the cognitive effects of prucalopride in people who are currently experiencing low mood.
The study will use an experimental medicine approach to examine the effects of 5-HT4R activation on cognitive processes relevant to depression. In addition, the study will investigate the effect of prucalopride on sleep architecture. Sleep will be assessed in the home environment using wearable chest patches capable of sleep staging.
The study will provide proof-of-concept evidence regarding the effects of 5-HT4R activation on cognition and sleep in people experiencing low mood. These data will inform the design and feasibility of a future randomised controlled trial evaluating prucalopride in people with depression and cognitive impairment.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Susannah Murphy, PhD
- Phone Number: +441865618313
- Email: susannah.murphy@psych.ox.ac.uk
Study Contact Backup
- Name: Finley T Watton, MBiomedSci Neurosciences
- Phone Number: +447593941882
- Email: finley.watton@psych.ox.ac.uk
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7JX
- Recruiting
- Warneford Hospital
-
Principal Investigator:
- Susannah E Murphy, DPhil
-
Contact:
- Susannah Murphy, PhD
- Phone Number: +441865618313
- Email: susannah.murphy@psych.ox.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18-65
- Male or female
- Participant is willing and able to give informed consent for participation in the research
- Body mass index in the range of 18-35 inclusive
- Current PHQ-9 score in the range of 9-15
Exclusion Criteria:
- Any current or previous episode of a severe mental illness, other than Depressive Disorder. Comorbid Anxiety disorders will be allowed, but not OCD or PTSD.
- A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia
- Body Mass Index outside the range of 18 to 35 inclusive
- Any significant current medical condition likely to interfere with conduct of the study or analysis of data
- Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion)
- Ongoing psychopharmacological treatment for depression, including hypnotics (psychotherapy will be allowed as long as not newly-started in the last 6 weeks)
- High consumption of illicit substances to an extent that would make complying with study protocol challenging (including alcohol, caffeine, nicotine)
- Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study
- Currently pregnant, trying to get pregnant, or breast feeding
- Current, or a significant history of, gastro-intestinal disorder or irritable bowel syndrome
- Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose
- Participation in a study that involves the use of a medication or novel vaccine within the last three months
- Participation in a study using the same tasks in the last year
- Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging, including yellow/blue colourblindness
- A head injury causing concussion or loss of consciousness within the last six months
- Moderate to high risk of suicide or self-harm
- Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Chief Investigator.
Additional Exclusion Criteria for Participants in the Sleep Study Cohort:
- Unable to undergo cardiac monitoring
- Unable to wear the sleep patch device for full monitoring period
- Implanted neurostimulator or pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Prucalopride
Participants will receive daily oral prucalopride for 14 days. |
Prucalopride will be administered orally once daily for 14 days. Participants will receive 1 mg once daily on Days 1-2 and 2 mg once daily on Days 3-14. |
|
Placebo Comparator: Placebo
Participants will receive daily oral placebo for 14 days. |
A matching placebo (lactose) will be administered orally once daily for 14 days. Participants will take one placebo capsule on Days 1-2 and two placebo capsules on Days 3-14, matching the dosing schedule of the prucalopride intervention. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Auditory Verbal Learning Test (AVLT)
Time Frame: Day 14 (post-intervention)
|
Verbal learning and memory will be assessed using the Auditory Verbal Learning Test, including measures of immediate recall, delayed recall, and recognition memory. AVLT performance will be compared between prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep outcomes measured using wearable sleep monitoring
Time Frame: Baseline (Day 0) and Days 1-4 of the intervention
|
Sleep will be assessed using a wearable chest patch in a subset of participants (n=20 total, 10 per intervention group). Measures will include sleep duration, sleep quality and sleep staging. Sleep outcomes will be compared between the prucalopride and placebo groups. |
Baseline (Day 0) and Days 1-4 of the intervention
|
|
Digit Span Task
Time Frame: Baseline and Day 14 (post-intervention)
|
Maximum digit span will be assessed as a measure of working memory and compared between the prucalopride and placebo groups |
Baseline and Day 14 (post-intervention)
|
|
Emotional Go/No-Go (EGNG)
Time Frame: Day 14 (post-intervention)
|
Inhibitory control will be assessed using the EGNG task, including measures of commission errors, omission errors, and reaction time. Performance will be compared between prucalopride and placebo groups follwing the intervention. |
Day 14 (post-intervention)
|
|
Probabilistic Reversal Learning Task (PRL)
Time Frame: Day 14 (post-intervention)
|
Cognitive flexibility and reward-based learning will be assessed using the PRL task, including measures such as response accuracy, reversal errors, and sensitivity to reward and punishment. Performance will be compared between prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
|
Mnemonic Similarity Task (MST)
Time Frame: Day 14 (post-intervention)
|
Pattern separation and recognition memory will be assessed using the MST. Performance will be compared between the prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
|
Serial Addition Task (SAT)
Time Frame: Day 14 (post-intervention)
|
Working memory will be assessed using the SAT. Performance will be compared between the prucalopride and placebo groups following the intervention |
Day 14 (post-intervention)
|
|
Matrix Span Task
Time Frame: Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
|
Visual working memory assessed using the Matrix Span Task, administered remotely via the NeuroUX app. Performance (accuracy/reaction time) will be compared between prucalopride and placebo groups. |
Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
|
|
Variable Difficulty List Memory Test (VDLMT)
Time Frame: Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
|
Verbal learning and recognition memory will be assessed using the VDLMT, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
|
|
N-Back Test
Time Frame: Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
|
Working memory will be assessed using the 2-back version of the N-back task, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
|
|
Digit Symbol Substitution Task (DSST)
Time Frame: Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
|
Processing speed will be assessed using the DSST, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
|
|
Quick Tap 2 Test
Time Frame: Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
|
Response inhibition will be assessed using the Quick Tap 2 test, a go/no-go task administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
|
|
Paired Associates Learning (PAL)
Time Frame: Day 14 (post-intervention)
|
Verbal associative and episodic memory will be assessed using the PAL task. Performance will be compared between the prucalopride and placebo groups. |
Day 14 (post-intervention)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
State Subjective Cognition Scale (SSCS)
Time Frame: Baseline and daily during the 14-day intervention.
|
Subjective cognitive functioning will be assessed using the State Subjective Cognition Scale (SSCS). Responses will be compared between the prucalopride and placebo groups. |
Baseline and daily during the 14-day intervention.
|
|
Positive and Negative Affect Schedule (PANAS)
Time Frame: Baseline and daily during the 14-day intervention.
|
Positive and negative affect will be assessed using the PANAS. Scores will be compared between the prucalopride and placebo groups. |
Baseline and daily during the 14-day intervention.
|
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, Day 7 and Day 14 of the intervention
|
Depressive symptoms will be assessed using the PHQ-9. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention
|
|
Perceived Deficits Questionnaire (PDQ)
Time Frame: Baseline, Day 7 and Day 14 of the intervention
|
Subjective cognitive difficulties will be assessed using the PDQ. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, Day 7 and Day 14 of the intervention.
|
Anxiety symptoms will be assessed using the GAD-7. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention.
|
|
Temporal Experience of Pleasure Scale (TEPS)
Time Frame: Baseline, Day 7 and Day 14 of the intervention.
|
Anticipatory and consummatory pleasure will be assessed using the TEPS. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Susannah E Murphy, DPhil, Department of Psychiatry, University of Oxford
Publications and helpful links
General Publications
- Ahern E, White J, Slattery E. Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis. Neuropsychol Rev. 2025 Mar;35(1):1-34. doi: 10.1007/s11065-023-09629-9. Epub 2024 Feb 5.
- De Giorgi R, Waters S, Gillespie AL, Quinton AMG, Colwell MJ, Murphy SE, Cowen PJ, Harmer CJ. Effects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial. Psychol Med. 2025 May 22;55:e155. doi: 10.1017/S0033291725001187.
- Colwell MJ, Tagomori H, Chapman S, Gillespie AL, Cowen PJ, Harmer CJ, Murphy SE. Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research. Transl Psychiatry. 2022 Nov 17;12(1):484. doi: 10.1038/s41398-022-02249-6.
- de Cates AN, Harmer CJ, Harrison PJ, Cowen PJ, Emmanuel A, Travis S, Murphy SE, Taquet M. Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial. Br J Psychiatry. 2024 Sep;225(3):371-378. doi: 10.1192/bjp.2024.97.
- Singh S, Strong R, Xu I, Fonseca LM, Hawks Z, Grinspoon E, Jung L, Li F, Weinstock RS, Sliwinski MJ, Chaytor NS, Germine LT. Ecological Momentary Assessment of Cognition in Clinical and Community Samples: Reliability and Validity Study. J Med Internet Res. 2023 Jun 2;25:e45028. doi: 10.2196/45028.
- de Cates AN, Wright LC, Martens MAG, Gibson D, Turkmen C, Filippini N, Cowen PJ, Harmer CJ, Murphy SE. Deja-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Transl Psychiatry. 2021 Oct 4;11(1):497. doi: 10.1038/s41398-021-01568-4.
- Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med. 2020 Dec;50(16):2722-2730. doi: 10.1017/S0033291719002836. Epub 2019 Oct 16.
- Murphy SE, de Cates AN, Gillespie AL, Godlewska BR, Scaife JC, Wright LC, Cowen PJ, Harmer CJ. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021 May;51(7):1111-1120. doi: 10.1017/S0033291720000604. Epub 2020 Apr 3.
- Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011 Jun;41(6):1165-74. doi: 10.1017/S0033291710001911. Epub 2010 Oct 8.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PROMOTE (2544373)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Anonymised individual participant data (IPD) that underlie the results reported in publications arising from this study will be available to researchers upon request, subject to appropriate ethical, data protection and institutional requirements
IPD Sharing Time Frame
Available following the publication of the study results
IPD Sharing Access Criteria
Available to researchers on request, subject to approal by the study team/institution and applicable ethical and data protection requirements
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.